IN8bio, INC.

General Information

We are a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue.

 We are the first company to advance genetically modified gamma-delta T cells into the clinic, leveraging the powerful and naturally occurring anti-cancer properties of these cells to enable their use in combination with therapeutic administration of chemotherapy. We are conducting two investigator-initiated Phase 1 clinical trials for both of our lead gamma-delta T cell product candidates: INB-200, to treat newly diagnosed glioblastoma, or GBM, and INB-100, to treat patients with leukemia undergoing hematopoietic stem cell transplantation, or HSCT. (Glioblastoma is one of the most aggressive types of cancer that typically starts in the brain or the spinal cord, according to the Mayo Clinic.)




Employees: 7
Founded: 2016
Contact Information
Address 79 Madison Avenue, New York, New York 10016
Phone Number (646) 600-6438
Web Address
View Prospectus: IN8bio, INC.
Financial Information
Market Cap $310.9mil
Revenues $0 mil (last 12 months)
Net Income $-7.3 mil (last 12 months)
IPO Profile
Symbol INAB
Exchange NASDAQ
Shares (millions): 4.7
Price range $15.00 - $17.00
Est. $ Volume $75.2 mil
Manager / Joint Managers Barclays/ Cantor/ Mizuho Securities
Expected To Trade: 11/13/2020
Status: Postponed
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change